Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
DX3CUM
|
||||
Drug Name |
N-(1-((cyanomethyl)carbamoyl)cyclohexyl)-5-bromothiophene-2-carboxamide
|
||||
Synonyms |
CHEMBL200167
|
||||
Indication | Discovery agent | Investigative | [1587926] | ||
Formula |
C14H16BrN3O2S
|
||||
Canonical SMILES |
Brc1ccc(s1)C(=O)NC2(CCCCC2)C(=O)NCC#N
|
||||
InChI |
InChI=1S/C14H16BrN3O2S/c15-11-5-4-10(21-11)12(19)18-14(6-2-1-3-7-14)13(20)17-9-8-16/h4-5H,1-3,6-7,9H2,(H,17,20)(H,18,19)
|
||||
InChIKey |
MYQWFADAHVCPFY-UHFFFAOYSA-N
|
||||
Target and Pathway | |||||
Target(s) | Cathepsin L | Target Info | [1587926] | ||
Cathepsin B | Target Info | [1587926] | |||
Reactome | Endosomal/Vacuolar pathway | ||||
Collagen degradation | |||||
Degradation of the extracellular matrix | |||||
Trafficking and processing of endosomal TLR | |||||
Assembly of collagen fibrils and other multimeric structures | |||||
MHC class II antigen presentationR-HSA-1442490:Collagen degradation | |||||
MHC class II antigen presentation | |||||
WikiPathways | Primary Focal Segmental Glomerulosclerosis FSGS | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.